J. Biol. Chem.
Rational Design of a Parthenolide-based Drug Regimen That Selectively Eradicates Acute Myelogenous Leukemia Stem Cells.
Pei, S., Minhajuddin, M., D’Alessandro, A., Nemkov, T., Stevens, B.M., Adane, B., Khan, N., Hagen, F.K., Yadav, V.K., De, S., Ashotn, J.M., Hansen, K.C., Gutman, J.A., Pollyea, D.A., Crooks, P.A., Smith, C., and Jordan, C.T.
Notes: A triple drug treatment-parthenolide, 2-deoxyglucose, and temsirolimus (PDT); each chosen for the ability to inhibit the pentose phosphate pathway and the Nrf-2-mediated anti-oxidant reponse-was tested against AML cells, leukemic stem/progenitor cells and normal heamtopoietic counterparts. The PDT treatment was potently toxic to the AML and leukemic stem/progentor cells with little toxicity to the normal cells. The NADPH and GSH/GSSG ratios were monitored in this study with the NADP/NADPH-Glo™ Assay and GSH/GSSG-Glo™ Assay. (4856)
Expand Full Notes »